In the last trading session, 2.33 million shares of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) were traded, and its beta was 1.05. Most recently the company’s share price was $0.69, and it changed around -$0.02 or -3.28% from the last close, which brings the market valuation of the company to $249.43M. LXRX currently trades at a discount to its 52-week high of $3.73, offering almost -440.58% off that amount. The share price’s 52-week low was $0.62, which indicates that the current value has risen by an impressive 10.14% since then. We note from Lexicon Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.47 million shares, with the 3-month average coming to 4.84 million.
Lexicon Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended LXRX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Lexicon Pharmaceuticals Inc is expected to report earnings per share of -0.12 for the current quarter.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Instantly LXRX has showed a red trend with a performance of -3.28% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.7650 on recent trading dayincreased the stock’s daily price by 9.8%. The company’s shares are currently down -6.57% year-to-date, but still down -9.95% over the last five days. On the other hand, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is -10.38% down in the 30-day period. We can see from the shorts that 33.5 million shares have been sold at a short interest cover period of 6.41 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 88.5% from its current value. Analyst projections state that LXRX is forecast to be at a low of $6 and a high of $6.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Lexicon Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -67.61 percent over the past six months and at a 16.46% annual growth rate that is well below the industry average of 16.50%. The year-over-year growth rate is expected to be 824.52%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 6.48M in revenue for the current quarter. 3 analysts expect Lexicon Pharmaceuticals Inc to make 3.05M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 702k and 1.13M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 822.99%. Forecasts for the next quarter put sales growth at 169.94%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.80%.
LXRX Dividends
Lexicon Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in February.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.15% of Lexicon Pharmaceuticals Inc shares, and 81.95% of them are in the hands of institutional investors. The stock currently has a share float of 82.90%. Lexicon Pharmaceuticals Inc stock is held by 183.0 institutions, with ARTAL GROUP S.A. being the largest institutional investor. By 2024-06-30, it held 71.3555% of the shares, which is about 175.1 million shares worth $294.17 million.
FMR LLC, with 15.7656% or 38.69 million shares worth $64.99 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Growth Company Fund and Fidelity Growth Company K6 Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 17.24 shares worth $11.9 million, making up 4.77% of all outstanding shares. On the other hand, Fidelity Growth Company K6 Fund held roughly 5.62 shares worth around $3.88 million, which represents about 1.56% of the total shares outstanding.